Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949241 | 0.92 | ERBB2 (0.74) | EGFRERBB2LCKERBB4AURKA | |
| SCHEMBL8309178 | 0.86 | EGFR (0.70) | EGFRERBB2LCKERBB4AURKA | |
| SCHEMBL8310027 | 0.85 | EGFR (0.66) | EGFRERBB2LCKERBB4AURKA | |
| SCHEMBL8308380 | 0.85 | EGFR (0.82) | EGFRERBB2LCKERBB4AURKA | |
| SCHEMBL11902491 | 0.82 | ERBB2 (0.63) | EGFRERBB2LCKERBB4AURKA | |
| SCHEMBL8307102 | 0.80 | EGFR (0.76) | EGFRERBB2LCKERBB4AURKA | |
| SCHEMBL4560407 | 0.79 | EGFR (0.76) | EGFRERBB2LCKERBB4AURKA | |
| SCHEMBL8309272 | 0.79 | EGFR (0.76) | EGFRERBB2LCKERBB4AURKA | |
| SCHEMBL8307584 | 0.79 | ERBB2 (0.68) | EGFRERBB2LCKERBB4AURKA | |
| SCHEMBL22967949 | 0.78 | ERBB2 (0.57) | EGFRERBB2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | CSNK1G3, CSNK1A1, CSNK1A1L | EGFR 3299/4885ERBB2 851/4885LCK 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.